GLP-1 Receptor Agonists vs Other Anti-Diabetics
A network meta-analysis compared GLP-1 receptor agonists to traditional anti-diabetes drugs based on hypoglycemia incidence, HbA1c goals, and more.
Dulaglutide Safety in Older Diabetic Patients
Researchers compared the safety and efficacy of a GLP-1 receptor agonist in patients aged 65 years or older to those under 65 years.
GLP-1 RA Efficacy with BMI
Does the body mass index of a diabetic patient have any effect on the efficacy of GLP-1 receptor agonists?
GLP-1 RA and Sleep Apnea
Can adding a GLP-1 receptor agonist to lifestyle changes improve obstructive sleep apnea management in your patients?
How Much Does GLP-1 RA Impact Glucose, Weight?
Clinical trials have shown that GLP-1 RAs reduce HbA1c and weight in type 2 diabetes, but are these outcomes confounded by concomitant medications?
Risk of Cardiovascular Events with Dulaglutide
A meta-analysis examined the effect of treatment with a GLP-1 receptor agonist on cardiovascular event risk in type 2 diabetes patients.
GLP-1 RA Effectiveness in Asian vs White Patients
Unlike typical Western patients, type 2 diabetes patients in Asia tend to have lower BMIs. Does this mean responses to GLP-1 RAs differ as well?
Adiposity and High CV Risk in Type 2 Diabetes
The LEADER trial of GLP-1 RA liraglutide examined anthropometric measures of adiposity and cardiovascular risk in type 2 diabetes patients.
Comparing Weight Loss with Liraglutide
Does a GLP-1 receptor agonist offer the same weight-loss benefits to different racial subgroups?
Patient-Reported Outcomes of Dulaglutide
How did dulaglutide measure up when compared to metformin or sitagliptin, insulin, or other GLP-1 receptor agonists?
Liraglutide with Moderate Renal Impairment
A clinical trial looks at the effects of a GLP-1 receptor agonist in poorly controlled type 2 diabetes patients with moderate renal impairment.
Benefits of GLP-1 Receptor Agonists in Teens
Certain factors may help determine which adolescents will receive the most weight loss benefits from GLP-1 receptor agonists.
Small Differences in GLP-1 Agonists Identified
Differences in four GLP-1 receptor agonists are noted, such as reductions in HbA1c, but are better studies needed to get a meaningful comparison?
What Do Patients Want in a Diabetes Medication?
A recent study looked at two GLP-1 agonists to compare 6 attributes of T2DM treatment and determine the importance patients placed on each one.
Cardiac Effects of GLP-1 RA
A small study examines the possibility of using GLP-1 RAs to improve ventricular ejection fraction in patients with STEMI.
GLP-1 RA and Nonalcoholic Steatohepatitis
GLP-1 RAs are effective for glycemic control, but can a phase II study show the drug is also effective for nonalcoholic steatohepatitis?
Poorly Controlled Type 2 Diabetes and GLP-1 RA
What happens when T2DM patients on daily insulin add a GLP-1 receptor agonist to their treatment?
Liraglutide’s Effect on HbA1c in Type 1 Diabetes
Adding the GLP-1 receptor agonist to insulin therapy resulted in decreased body weight and insulin requirements, but how did the drug affect HbA1c?
AWARD Trial Shows Promise for GLP-1 Agonist
Which GLP-1 receptor agonist showed improved HbAlc with no weight gain or hypoglycemia?
Once Weekly GLP-1 Receptor Agonist Phase II Trial
Despite the side effects experienced at a high dose, a long-acting GLP-1 agonist proceeds to phase III trials.
Reduced Body Weight in an Obese Population
Non-diabetic obese patients experienced many benefits from taking a GLP-1 agonist.
GLP-1 Receptor Agonists and Brain Glucose Metabolism
What effect did GLP-1 agonists have on brain glucose metabolism?
Surprising Finding: Alcohol and Thyroid Cancer
Is thyroid cancer the exception to the rule that alcohol consumption is linked to an increased risk of developing cancer?
Bariatric Surgery Better Corrected Diabetes vs. Lifestyle Alone
T2DM patients who underwent surgery experienced decreased use of diabetes medications, if not partial or complete disease remission.
CV Data Shows No Benefit, Risk to GLP-1 Receptor Agonist Lixisenatide
A large phase IIIb study showed no increased risk for cardiovascular problems with GLP-1 receptor agonist lixisenatide.
GLP-1 Agonists May Change How Brain Responds to Food
GLP-1 receptor agonists may help patients with type 2 diabetes to lose weight by altering the way their brains respond to food.
Chronic Exposure to Superantigen May Influence T2DM Risk
Chronic exposure to superantigens, such as Staphylococcus aureus, may play a role in impaired glucose metabolism and the development of type 2 diabetes in the overweight and obese.
GLP-1 Secretion Did Not Affect Pancreatic Amylase, Lipase Plasma Concentrations
Researchers study whether or not GLP-1 affects pancreatic amylase or lipase plasma concentrations.
GLP-1 Inhibitors May Have Duel Anti-Atherogenic Action
GLP-1 inhibition may have an anti-atherogenic action that involves both glucose and lipid metabolism.
Incretin Therapy Side Effects Linked to Age, No Metformin Use
GI side effects compel many patients to stop GLP-1 agonist therapy. A new study identifies important risk factors to consider before prescribing.
2 Clarke Drive Cranbury, NJ 08512